Claims
- 1. A stereoselective process for preparing an alpha-anomer enriched ribofuranosyl derivative of the formula ##STR2## wherein each X is independently selected from hydroxy protecting groups and Y is halo; comprising contacting a 3,5-hydroxy protected-2-deoxy-2,2-difluoro-D-ribofuranosyl-1-.beta. sulfonate with a halide source in an inert solvent.
- 2. The process of claim 1 wherein the halide source is selected from the group consisting of tetraalkylammonium halides, trialkylammonium halides, lithium halides, sodium halides, cesium halides and potassium halides.
- 3. The process of claim 2 wherein the halide source is selected from tetraalkylammonium halides.
- 4. The process of claim 3 wherein the halide source is selected from tetrabutylammonium bromide, tetrabutylammonium iodide and tetrabutylammonium fluoride.
- 5. The process of claim 1 wherein the amount of halide source is about 1 molar equivalent to about 5 molar equivalents.
- 6. The process of claim 1 wherein the solvent is selected from the group consisting of acetonitrile, dimethylformamide, tetrahydrofuran, N,N'-dimethylpropyleneurea, dichloromethane, and mixtures thereof.
- 7. The process of claim 6 wherein the solvent is selected from the group consisting of tetrahydrofuran, acetonitrile, and mixtures thereof.
- 8. The process of claim 1 wherein Y is iodo comprising contacting a 2-deoxy-2,2-difluoro-D-ribofuranosyl-1-.beta.-sulfonate with tetrabutylammonium iodide in acetonitrile.
- 9. The process of claim 1 wherein Y is bromo comprising contacting a 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-dibenzoyl-1-.beta.-sulfonate with potassium bromide in dimethylformamide.
- 10. The process of claim 1 wherein Y is iodo comprising contacting a 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-dibenzoyl-1-.beta.-sulfonate with tetrabutylammonium iodide in tetrahydrofuran.
- 11. The process of claim 1 wherein Y is bromo comprising contacting a 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-dibenzoyl-1-.beta.-sulfonate with tetrabutylammonium bromide in acetonitrile.
- 12. The process of claim 1 wherein Y is fluoro comprising contacting a 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-dibenzoyl-1-.beta.-sulfonate with tetrabutylammonium fluoride in tetrahydrofuran.
- 13. The process of claim 1 wherein the .beta.-sulfonate is 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-dibenzoyl-1-.beta.-(p-bromobenzene) sulfonate.
- 14. The process of claim 1 wherein the .beta.-sulfonate is 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-dibenzoyl-1-.beta.-(p-toluene) sulfonate.
- 15. The process of claim 1 wherein the .beta.-sulfonate is 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-dibenzoyl-1-.beta.-trifluromethanesulfonate.
- 16. The process of claim 1 wherein the .beta.-sulfonate is 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-dibenzoyl-1-.beta.-2,4-dinitrobenzenesulfonate.
- 17. The process of claim 1 further comprising adding a catalyst selected from crown ethers.
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a Continuation-In-Part of application Ser. No. 07/902,306, filed Jun. 22, 1992, now abandoned.
US Referenced Citations (5)
Non-Patent Literature Citations (1)
Entry |
Cancer Research, vol. 49, issued 01 Aug. 1989, Tietze et al, "Proton14 mediated Liberation of Aldophosphamide from a Nontoxic Prodrug: A Strategy for Tumor-Selective Activation of Cytocidal Drugs" pp. 4179-4184. |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
902306 |
Jun 1992 |
|